Adaptimmune Therapeutics PLC (NASDAQ: ADAP) shares jumped on Friday after the company announced updated data from its early-stage clinical trial in patients with lung, head and neck cancers.
Specifically, the firm presented updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology (ASCO) Annual Meeting.
The data demonstrated durability and responses in synovial sarcoma, supporting Spearhead-1 as a potential registrational trial. The ASCO presentation also described a new response in a patient with lung cancer, and a response in a patient with head and neck cancer (reported in January).
Separately, Adaptimmune announced new responses in the Surpass trial, confirming the potential for Spear T‑cell therapies targeting MAGE-A4 to treat a broad range of cancers in addition to sarcoma. These data further support the rationale for two new Phase 2 trials: Spearhead-2 in head and neck cancer, which will begin later this year, and a second trial in esophagogastric junction cancer planned for the first half of 2021.
Adrian Rawcliffe, CEO, commented:
I am pleased to announce that we have identified a new indication to progress into late stage development. We plan to initiate a Phase 2 trial in esophagogastric junction cancer in the first half of 2021, with our next-generation ADP-A2M4CD8 SPEAR T-cells. In addition, the ASCO data demonstrate promising durability for ADP-A2M4 in sarcoma bolstering our ambition to have our first marketed therapy in 2022. I’m thrilled with the responses in a broad range of tumors with our programs targeting MAGE-A4 and AFP. I am confident that we will be able to identify more indications for late stage development as more patients are treated in our trials.
Adaptimmune Therapeutics stock traded up about 72% on Friday, at $8.36 in a 52-week range of $0.71 to $10.19. The consensus price target is $4.40.
24/7 Wall St.Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
